Join Mission Bio for an interactive virtual seminar highlighting the key advantages of single-cell technology that simultaneously measures single-nucleotide variation (SNV), copy number variation (CNV), and protein data from the same cells. Our multi-omics platform connects genotype and phenotype in each cell, dissecting the architecture of tumors with unprecedented resolution.
We are happy to welcome Dr. Sandra Misale, Memorial Sloan Kettering Cancer Center. She will present data from her latest publication "Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers." (2022).
In addition, Simone Formisano will give an introduction to Mission Bio's Tapestri capabilities on SNV, CNV, and protein sequencing at scale, the workflow and its applications in oncology and cell and gene therapy.
Date: Wednesday, June 29, 2022
Time: 16:00 - 17:00h CEST
| Speakers | ||
 |
Sandra Misale, PhD Dr. Sandra Misale is working as research associate in Dr. Neal Rosen laboratory at the Memorial Sloan Kettering Cancer Center. Sandra’s current research focuses on developing rational combinations to overcome drug resistance in melanoma, lung and colorectal cancers, exploring pharmacological characterization and targeting of upstream-driven feedbacks of MAPK pathway as well as antibody-drug conjugates. |
|
 |
Simone Formisano Simone Formisano is Technical Application Liaison at Mission Bio. He obtained his Master's Degree in Biotechnology at Columbia University, New York City (United States). Before joining Mission Bio in 2022, Simone completed his Doctorate experimental work in cancer immunotherapy at Ludwig Maximilian University of Munich. Afterward, he contributed to the clinical development of several therapies in solid oncology by joining Daiichi Sankyo as a Medical Science Liaison. |
